BioSpace News Archive

PostProcess Technologies Inc., the first and only global provider of automated and intelligent post-printing solutions for industrial 3D printing, has announced another patent granted in the United States. U.S. Patent No. 10,737,440, “

Submitted IND for PBGM01 Phase 1/2 trial; currently on FDA clinical hold pending additional review of proposed ICM delivery device

BioCardia®, Inc., a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, reported financial results and business highlights for the second quarter of 2020 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2020 with the Securities and Exchange Commission on August 13, 2020.

VBL Therapeutics announced financial results for the second quarter ended June 30, 2020, and provided a corporate update.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, reports its financial results for the second quarter ended June 30, 2020 and provides a corporate update.

WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in Europe

Micronoma, an early cancer-detection biotech that seeks to develop and commercialize a minimally invasive, microbiome-based method, announced that it has closed a $3 million seed financing round led by microbiome-focused investor, SymBiosis, LLC.

scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced financial results for the second quarter ended June 30, 2020 and provided a business update.

Heat Biologics, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, reported preclinical data for Heat’s gp96-based COVID-19.

AstraZeneca Ships FLUMIST ® QUADRIVALENT Vaccine in the US for 2020-2021 Flu Season Production increased in anticipation of higher demand due to COVID-19; Over 25% more US doses of the only nasal-spray vaccine to be available as soon as early August WILMINGTON, Del.--( BUSINESS WIRE )-- AstraZeneca today announced the first shipment of FLUMIST ® QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses in the US for the 2020-2021 influenza season. F